{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:27:10Z","timestamp":1767896830172,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018748","name":"argenx nv","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jns.2024.122907","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T12:37:14Z","timestamp":1706618234000},"page":"122907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Qualitative interviews to support development of a patient-reported companion measure to the Glucocorticoid Toxicity Index"],"prefix":"10.1016","volume":"458","author":[{"given":"Timothy A.","family":"Howell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis S.","family":"Matza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha N.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayaraghava T.S.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jns.2024.122907_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015905","article-title":"Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France","volume":"7","author":"Benard-Laribiere","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jns.2024.122907_bb0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"15","key":"10.1016\/j.jns.2024.122907_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000647","article-title":"Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study","volume":"94","author":"Fardet","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jns.2024.122907_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.jns.2024.122907_bb0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaip.2020.09.001","article-title":"The vexed problem of corticosteroid toxicity in asthma: time for standardized assessment","volume":"9","author":"Beasley","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.jns.2024.122907_bb0030","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2009.114579","article-title":"Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the european league against rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.jns.2024.122907_bb0035","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s12098-008-0211-6","article-title":"Strategies for minimizing corticosteroid toxicity: a review","volume":"75","author":"Aulakh","year":"2008","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.jns.2024.122907_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.jns.2024.122907_bb0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of anca-associated vasculitis","volume":"384","author":"DRW","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.122907_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdin.2021.09.003","article-title":"Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the glucocorticoid toxicity index: a cohort study","volume":"6","author":"Liang","year":"2022","journal-title":"JAAD Int."},{"issue":"1","key":"10.1016\/j.jns.2024.122907_bb0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaip.2020.08.032","article-title":"Quantification of glucocorticoid-associated morbidity in severe asthma using the glucocorticoid toxicity index","volume":"9","author":"McDowell","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.jns.2024.122907_bb0060","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00160-2021","article-title":"Glucocorticoid toxicity reduction with mepolizumab using the glucocorticoid toxicity index","volume":"59","author":"McDowell","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.jns.2024.122907_bb0065","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TITAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"10.1016\/j.jns.2024.122907_bb0070","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jns.2024.122907_bb0075","series-title":"Patient-Focused Drug Development: Methods to Identify What Is Important to Patients","first-page":"1","author":"Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.jns.2024.122907_bb0080","series-title":"Patient-Focused Drug Development: Collecting Comprehensive and Representative Input","first-page":"1","author":"Food and Drug Administration","year":"2020"},{"issue":"235","key":"10.1016\/j.jns.2024.122907_bb0085","first-page":"65132","article-title":"Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims","volume":"74","author":"Food and Drug Administration","year":"2009","journal-title":"Fed. Regist."},{"issue":"8","key":"10.1016\/j.jns.2024.122907_bb0090","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (pro) instruments for medical product evaluation: Ispor pro good research practices task force report: Part 2--assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jns.2024.122907_bb0095","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and us costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.jns.2024.122907_bb0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00019053-200826050-00002","article-title":"Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment","volume":"26","author":"Leidy","year":"2008","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"10.1016\/j.jns.2024.122907_bb0105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11136-011-9990-8","article-title":"Content validity of patient-reported outcome measures: perspectives from a promis meeting","volume":"21","author":"Magasi","year":"2012","journal-title":"Qual. Life Res."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:05:02Z","timestamp":1758384302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2400042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":21,"alternative-id":["S0022510X2400042X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.122907","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Qualitative interviews to support development of a patient-reported companion measure to the Glucocorticoid Toxicity Index","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.122907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122907"}}